Celgene Corporation

Celgene — Merger or Acquisition (July 2015)

29 slides from Celgene's merger presentation, Jul 15, 2015

  1. Slide 1: Celgene Announces Acquisition of Receptos

    Celgene Announces Acquisition of Receptos July 14, 2015

  2. Slide 2: Agenda

    Agenda 2 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celgen

  3. Slide 3: Forward Looking Statements and Adjusted Financial Information

    Forward Looking Statements and Adjusted Financial Information Thi s presentatio n contain s forward - lookin g statements , whic h ar e generall y s tatement s tha t ar e not historica l facts . Forward - lookin g s tatement s ca n b e identifie d b y th e word s “ expects, ” “anticipates,” “believe

  4. Slide 4: Additional Information on the Tender Offer

    Additional Information on the Tender Offer The tender offer described herein has not yet commenced. The description contained herein is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of Receptos. At the time the tender offer is commenced

  5. Slide 5: Agenda

    Agenda 5 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celgen

  6. Slide 6: Our Mission and Vision

    Our Mission and Vision Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune - inflammatory diseases 6

  7. Slide 7: Our Focus: Executing on Five Strategic Imperatives

    OUR FOCUS: Executing on Five Strategic Imperatives Operational excellence Capitalizing on strength in Hematology Expanding the Oncology franchise Sustaining innovation and long - term growth Building an Immunology & Inflammation franchise 7

  8. Slide 8: Operational Excellence

    Operational Excellence • Exceptional Q2:15 Financial Performance (preliminary) – Total Revenue of approximately $2.28 billion, 22% year - over - year increase – Adjusted EPS of approximately $1.23, including a $0.06 gain on the sale of an equity investment, 37% year - over - year increase • Signific

  9. Slide 9: Sustaining Innovation and Long-Term Growth

    Sustaining Innovation and Long - Term Growth • Added Significant Next - generation Growth Drivers – Deals with AstraZeneca, Juno, and Receptos enhance our existing pipeline by adding the potential of 4 product approvals in multiple diseases by 2020 – Accelerated revenue and earnings growth expected

  10. Slide 10: Ozanimod Is a Strong Strategic Fit with Significant Potential

    x Leverages existing I&I capabilities and future IBD commercial infrastructure x Neutral to adjusted EPS in 2018; accretive beginning in 2019 x Raising 2020 targets to $ 21B+ in revenue (+$1B) & $13.00+ in adjusted EPS (+$0.50) Financially Compelling Ozanimod Is a Strong Strategic Fit with Significa

  11. Slide 11: Agenda

    Agenda 11 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge

  12. Slide 12: Receptos is a Strong Strategic Fit for Celgene I&I

    Receptos is a Strong Strategic Fit for Celgene I&I Disruptive I&I Products • Ozanimod is a potential best - in - class oral S1P receptor modulator in late - stage development presenting a $4B - $6B peak sales opportunity • Ozanimod advancing in Phase III for Ulcerative Colitis and Relapsing Multiple

  13. Slide 13: Combined Robust and Deep I&I Pipeline

    Programs and Indications Pre - Clinical Phase I Phase II Phase III Reg. Approval OTEZLA (PDE4 inhibitor) Psoriatic Arthritis Psoriasis Beh ç et Syndrome Ankylosing Spondylitis Atopic Dermatitis Ulcerative colitis GED - 0301 (Smad7 antisense oligo) Crohn’s Disease Ulcerative Colitis (planned) Ozanimo

  14. Slide 14: Phase III Ozanimod Data Expected Beginning in H1:17

    Phase III Ozanimod Data Expected Beginning in H1:17 14 • RADIANCE: Phase II / III trial in R elapsing Multiple Sclerosis – Enrollment completed in March 2015 – Data expected in H1:17 • SUNBEAM: Phase III trial in Relapsing Multiple Sclerosis – Enrollment initiated December 2014 – Data expected in H1

  15. Slide 15: Accelerating Momentum in the I&I Portfolio

    Accelerating Momentum in the I&I Portfolio Celgene existing Receptos 15 1 Under co - development option with AbbVie Multiple Blockbuster Products Expected in I&I Significant Growth through 2020 and beyond OTEZLA ® PsA / Psor 2014 Ozanimod RMS 2018E Ozanimod UC 2019E GED - 0301 CD 2019E

  16. Slide 16: Celgene I&I Targets Sizable Evolving Markets with Disruptive Oral Therapies

    Celgene I&I Targets Sizable Evolving Markets with a Portfolio of Disruptive Oral Therapies 16 Celgene I&I Portfolio Rheumatology Dermatology Gastroenterology / IBD Neuro - Inflammation Therapeutic Area Market Size ($B) 2014E 2020E $27 $34 $11 $17 $9 $15 $20 $27 Total ($B) $67 $93 Targeted Indication

  17. Slide 17: Agenda

    Agenda 17 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge

  18. Slide 18: Ozanimod: Potential Best-in-Class Oral S1PR Modulator

    Ozanimod: Potential Best - in - Class Oral S1PR Modulator Transformational Potential in UC, MS and Beyond • Highly selective for S1P1 & S1P5 • Negligible S1P3 activity = less CV tox • PK – delayed C max , T 1/2 , V d • No pro - drug Dose - Attuned Titration Schedule Intrinsic Properties: Product Att

  19. Slide 19: Ozanimod: A Potentially Transformational Profile in UC

    Ozanimod: A Potentially Transformational Profile in UC Ozanimod Induction of Remission and Response Mucosal Healing Once - daily Oral Dosing AEs & SAEs Similar to Placebo Rapid Onset of Efficacy 32 - Week Maintenance 19 x Novel oral treatments x Effective treatments to induce clinical response and t

  20. Slide 20: Tremendous Opportunity for Ozanimod to Disrupt the UC Treatment Paradigm

    Tremendous Opportunity for Ozanimod to Disrupt the UC Treatment Paradigm Expected Positioning of UC Treatments 1 st line treatment 2 nd line treatment 3rd line treatment Last line treatment 5 - Aminosalicylates Immunosuppressants and Corticosteroids Tysabri ® Ozanimod Remicade ® Humira ® Entyvio ® 4

  21. Slide 21: TOUCHSTONE Trial Results Reveal Transformational Potential in Moderate-to-Severe UC

    6.2% 9.3% 8.5% 16.4% 16.5% 17.3% 0% 5% 10% 15% 20% Ozanimod Wk 8 Phase II Humira Wk 8 Phase III Ozanimod Wk 32 Phase II Humira Wk 52 Phase III TOUCHSTONE Trial Results Reveal Transformational Potential for Ozanimod in the Treatment of Moderate - to - Severe UC • Efficacy: – Met primary efficacy and

  22. Slide 22: Ozanimod Addresses Significant Unmet Medical Needs in Relapsing MS

    x Therapies that offer improved disease control for relapsing forms of MS x Additional safe and well - tolerated oral therapies x Therapies appropriate for long - term use x Agents that halt and / or reverse disability Unmet Needs in RMS Differentiated Clinical Profile Current profile based on Phase

  23. Slide 23: Orals to Represent ~70% of the $27B MS Market in 2020

    Orals to Represent 60 - 70% of the $27B MS Market in 2020 $0 $15 $494 $1,204 $3,029 $5,957 $17,500 $0 $5,000 $10,000 $15,000 $20,000 2009 2010 2011 2012 2013 2014 2020E Ozanimod: Best - in - Class S1P1 Potential for Utilization in First - Line RMS * = Oral treatment Newly diagnosed 1 st line treatme

  24. Slide 24: Cross Trial Comparisons of Select Oral MS Therapies

    Ozanimod Phase II Efficacy Comparison to GILENYA ® and TECFIDERA ® 82% 55% 90% 53% 74% 44% 86% 31% 86% 53% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% GD+ Lesion Reduction* ARR Reduction* GILENYA FREEDOMS (0.5mg qd) TECFIDERA DEFINE (240mg bid) TECFIDERA CONFIRM (240mg bid) Ozanimod 0.5mg Phase II *

  25. Slide 25: Agenda

    Agenda 25 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge

  26. Slide 26: Transaction Overview

    Acquisition leverages our commercial structure / expertise, further diversifies revenue and enhances long - term growth Transaction Overview 26 Consideration Financing Financial benefits Other • All - cash consideration of $232 per share • Total transaction value of $7.2 billion, net of cash • Sourc

  27. Slide 27: Celgene Announces Acquisition of Receptos

    Celgene Announces Acquisition of Receptos July 14, 2015

  28. Slide 28: Reconciliation Tables

    A ZA Celgene © Reconciliation Tables

  29. Slide 29: wen soun nba we os uo wed aot pared

    wen soun nba we os uo wed aot pared uum RON ue EY “SEY ‘sueunape cu soley poms a peg si pagaruoumbve mG) ‘pany ) “(eany) 2 yoreesey somuogny euaijap pe sxesqy “Qas2om99) do aay ‘uaa uogesvaiuos pst. ‘sea ssa ap say pocunoure 2930 no20 Kew yep (suey) rT ur ‘suowsnboe ose i ( suns jo voneundyy ‘sda, f

Celgene — Merger or Acquisition (July 2015) on 6ix